Back Hepatitis B

Hepatitis B

Human Stem Cells Used to Create Functional Liver Cells in Mice

Researchers have discovered a way to generate functional hepatocytes (liver cells) from human stem cells, which worked as expected and increased survival when transplanted into mice with acute liver injury, researchers reported in the July 9, 2013, advance online edition of Stem Cells and Development.

alt

 

Read more:

Hepatitis B Treatment with Entecavir Lowers Risk of Liver Cancer

Long-term treatment with entecavir (Baraclude) significantly reduces the chances of developing hepatocellular carcinoma compared with no treatment, and appears to lower the risk more than an older drug, especially for the most at-risk patients, according to a report in the July 2013 issue of Hepatology.

alt

Read more:

DDW 2013: Does HBV Suppression Prevent Liver Disease Progression?

Chronic hepatitis B patients with cirrhosis may still experience liver disease progression even if they undergo antiviral treatment and achieve good virological response, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.

alt

Read more:

July 28 Is World Hepatitis Day

Sunday, July 28, is World Hepatitis Day, an opportunity to raise awareness about viral hepatitis and its consequences. The World Hepatitis Alliance theme for 2013 -- See No Evil, Hear No Evil, Speak No Evil -- emphasizes that hepatitis B and C are receiving inadequate attention worldwide, despite the large number of people affected and the high burden on healthcare systems.

alt

Read more:

Low Vitamin D Linked to Greater Hepatitis B Virus Replication

Low blood levels of 25-hydroxyvitamin D were strongly associated with higher hepatitis B virus (HBV) viral load in a study of more than 200 untreated patients described in the May 22, 2013 advance online edition of Hepatology.

alt

Read more:

WHO Releases Global Policy Report on Prevention and Control of Viral Hepatitis

In advance of World Hepatitis Day (June 28), the World Health Organization (WHO) this week released its first country-by-country hepatitis survey, covering viral hepatitis prevention and control efforts in 126 member states.

alt

Read more:

DDW 2013: Tenofovir and Entecavir Effectively Suppress Hepatitis B Virus

The newer antivirals tenofovir (Viread) and entecavir (Baraclude) inhibit hepatitis B virus (HBV) replication more effectively than older agents, but good adherence is needed to maintain long-term viral suppression, according to a set of studies presented at the Digestive Disease Week meeting (DDW 2013) last month in Orlando.

alt

Read more:

IAS 2013: Many People Need Hepatitis B Treatment in the Gambia

About 8% of people tested through a community-based screening program in the Gambia have hepatitis B, and about 8% of these have advanced liver disease and meet European criteria for antiviral therapy, according to a report presented at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this month in Kuala Lumpur.

alt

Read more:

Coverage of Digestive Disease Week 2013

HIVandHepatitis.com coverage of the 2013 Digestive Disease Week annual meeting (DDW 2013) in Orlando, Florida, May 18-21, 2013.

Conference highlights include direct-acting hepatitis C drugs, new strategies for using approved HCV protease inhibitors and interferon/ribavirin, and interferon-free regimens.

Full listing by topic

HIVandHepatitis.com DDW 2013 conference section

5/22/13alt